Urovant Sciences (NASDAQ:UROV) Announces Earnings Results
Urovant Sciences (NASDAQ:UROV) released its quarterly earnings results on Tuesday. The company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.02), Morningstar.com reports.
Shares of Urovant Sciences stock traded down $0.38 during trading on Wednesday, reaching $7.16. The company’s stock had a trading volume of 1,101 shares, compared to its average volume of 53,734. Urovant Sciences has a 52-week low of $4.05 and a 52-week high of $14.49. The company has a market cap of $227.55 million and a P/E ratio of -1.62. The firm has a 50-day simple moving average of $8.24. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 0.18.
A number of research firms have commented on UROV. HC Wainwright set a $28.00 price target on shares of Urovant Sciences and gave the stock a “buy” rating in a research note on Monday, June 24th. Zacks Investment Research cut shares of Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. JPMorgan Chase & Co. set a $24.00 price objective on shares of Urovant Sciences and gave the company a “buy” rating in a research note on Friday, June 14th. Finally, ValuEngine raised shares of Urovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $21.63.
Large investors have recently bought and sold shares of the stock. Barclays PLC purchased a new position in Urovant Sciences during the fourth quarter worth about $37,000. Two Sigma Investments LP purchased a new position in Urovant Sciences during the fourth quarter worth about $72,000. FMR LLC boosted its holdings in Urovant Sciences by 11.1% during the fourth quarter. FMR LLC now owns 1,332,701 shares of the company’s stock worth $8,782,000 after purchasing an additional 132,701 shares during the last quarter. Marshall Wace LLP purchased a new position in Urovant Sciences during the first quarter worth about $325,000. Finally, Marshall Wace North America L.P. purchased a new position in Urovant Sciences during the first quarter worth about $49,000. Institutional investors own 21.91% of the company’s stock.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Recommended Story: What is Liquidity?
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.